At Burzynski Clinic, we offer innovative, cutting-edge, Precision Personalized Cancer Therapy tailored to each patient’s unique needs. Backed by over 45 years of clinical experience and research, our approach delivers expert care for the best possible outcomes.
Our Approach to Cancer: Our goal is to provide sophisticated cancer care utilizing a personalized and precision-targeted immunotherapy approach.
Our personalized cancer therapy utilizes an understanding of each patient’s cancer genetic and immunotherapy make-up to unravel the biology of their cancer and to identify effective treatment strategies using targeted therapies and immunotherapies that are aimed at specific genes or proteins that are found only in cancer cells or their environment.
S. R. Burzynski, a nationally and internationally recognized physician/investigator, pioneered the use of biologically active peptides for the treatment of cancer. In 1967, at the age of 24, Dr. Burzynski graduated first in his class of 250 students from the Medical Academy in Lublin, Poland. It was at this time that he identified naturally occurring human peptides, which were deficient in cancer patients. He concluded that these peptides played a role in preventing the growth of cancer cells. In 1968, he earned a PhD degree and became one of the youngest physician/investigators in Poland to hold both a MD and PhD degree.
Dr. Burzynski has extensive experience investigating the use of Antineoplastons (ANPs) in the treatment of advanced cancers, especially malignant brain tumors, through patient participation in Phase II clinical trials.
Dr. Burzynski is the author/co-author of over 300 scientific publication/presentations. He has collaborated with investigators at the NCI, the Medical College of Georgia, the Imperial College of Science and Technology of London, the University of Kurume Medical School in Japan, and the University of Turin Medical School in Italy, among others. He is a member of several prestigious organizations, including the American Association of Cancer Research (AACR), the Society for Neuroscience, the Society for Neuro-oncology, the Royal Medical Association (U.K.), and the Academy of Medical Ethics. As of June 2015, he holds 244 patents in 35 countries covering 17 proprietary scientific inventions.
Founded in 1977, the Burzynski Research Institute (BRI) was established to advance the mission of the Burzynski Clinic: to beat cancer through innovative and personalized treatments. BRI is a biopharmaceutical company dedicated to developing and delivering cancer therapies rooted in genomic and epigenomic principles. Over the years, its research efforts have focused on Antineoplastons (ANPs), investigational agents that have shown promise in the treatment of advanced cancers, particularly malignant brain tumors.
BRI’s groundbreaking research has been explored in Phase I and II clinical trials. These efforts continue to support the clinic’s unwavering commitment to pioneering cancer treatments and advancing the understanding of cancer care. Through this ongoing research, Burzynski Clinic and BRI remain dedicated to delivering personalized, effective treatments that prioritize patient well-being while advancing the fight against cancer.
